Verified factor-similar pair

IWN vs VIOV

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB HML
Similarity score
91
Near substitute

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • VIOV has the higher backtested relative Sharpe (1.082 vs 0.994).
  • VIOV has the lower published fee (0.10% vs 0.24%).
  • VIOV is cheaper on dividend valuation (99 vs 131, where 100 is each fund's historical median).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

IWN

iShares Russell 2000 Value ETF
SMB HML
Adj. R2
0.978
Rel. Sharpe
0.994
Mkt beta
0.96
AUM
US$12.9B
MER
0.24%
Valuation
131

VIOV

Vanguard S&P Small-Cap 600 Value ETF
SMB HML
Adj. R2
0.979
Rel. Sharpe
1.082
Mkt beta
0.99
AUM
US$1.6B
MER
0.10%
Valuation
99

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
IWN
+0.83
|t|
+41.2
VIOV
+0.90
|t|
+32.1
diff -0.07
HML
IWN
+0.38
|t|
+18.3
VIOV
+0.35
|t|
+13.0
diff +0.02
RMW
IWN
+0.09
|t|
+3.9
VIOV
+0.10
|t|
+3.2
diff -0.02
CMA
IWN
+0.07
|t|
+2.3
VIOV
+0.05
|t|
+1.4
diff +0.01
UMD
IWN
+0.02
|t|
+1.9
VIOV
-0.04
|t|
-1.9
diff +0.06

Why This Pair Matches

Exposure level
89
Exposure shape
100
Mkt beta diff
0.02
Rel. Sharpe diff
0.089

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

IWN fund page VIOV fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.